Cutaneous Radiation Injuries (CRI)
Objective of ERMES project is to advance to licensure in USA topical formulation of BP-C2 for mitigation of localized cutaneous radiation injuries (CRI).
CRI may result from exposure to radioactive particles in the environment after a radiological/nuclear accident or emerge as a late side effect of skin irradiation in cancer patients.
The ERMES project encompasses vital studies to demonstrate the efficacy and safety of BP-C2 in animal models that reflect human responses to radiation damage (US FDA ‘Animal Rule’).
Based on a patented lignin-derived composition of polyphenols, BP-C2 exhibits pleiotropic biological effects mediated through multiple molecular targets involved in regulation of inflammation and DNA damage response.
Gastrointestinal injury (GI-ARS)
Gastrointestinal injury (GI-ARS) is another critical injury caused by deliberate (cancer care) and unintentional (radiation incidents) exposure to high doses (>5Gy) of radiation. GI-ARS requires efficient and safe countermeasures.
In cancer patients gastrointestinal system is often impaired by radiotherapy and cancer survivors may experience a range of acute and delayed effects of radiotherapy, which significantly impair their quality of life and treatment outcomes.
RDI is assessing efficacy and safety of oral formulation of BP-C2 in mitigation of gastrointestinal injuries following a whole-body or partial-body exposure of subjects to sub-lethal doses of ionizing radiation.